 Janet Kukreja
Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 15 | 2026 | 258 | 4.980 |
Why?
| | Cystectomy | 10 | 2025 | 42 | 3.660 |
Why?
| | Robotics | 3 | 2021 | 90 | 1.300 |
Why?
| | Robotic Surgical Procedures | 3 | 2021 | 185 | 1.120 |
Why?
| | Urology | 2 | 2024 | 63 | 0.780 |
Why?
| | Cystoscopy | 1 | 2021 | 21 | 0.680 |
Why?
| | Urinary Diversion | 1 | 2020 | 13 | 0.660 |
Why?
| | Smoking | 2 | 2019 | 1477 | 0.630 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 221 | 0.610 |
Why?
| | Urogenital Neoplasms | 1 | 2019 | 5 | 0.600 |
Why?
| | Ureter | 1 | 2020 | 36 | 0.600 |
Why?
| | Clinical Trials as Topic | 3 | 2026 | 1062 | 0.560 |
Why?
| | Urinary Bladder | 2 | 2020 | 196 | 0.550 |
Why?
| | Propensity Score | 1 | 2018 | 377 | 0.470 |
Why?
| | Neoplasm, Residual | 1 | 2017 | 143 | 0.470 |
Why?
| | Urologic Surgical Procedures | 1 | 2017 | 118 | 0.450 |
Why?
| | Organ Sparing Treatments | 2 | 2025 | 37 | 0.450 |
Why?
| | Cost-Benefit Analysis | 1 | 2018 | 644 | 0.440 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2015 | 68 | 0.440 |
Why?
| | Antineoplastic Agents | 1 | 2026 | 2219 | 0.420 |
Why?
| | Neoplasm Invasiveness | 5 | 2025 | 508 | 0.420 |
Why?
| | Anxiety | 1 | 2021 | 1122 | 0.400 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2026 | 1150 | 0.390 |
Why?
| | Aged | 14 | 2025 | 26217 | 0.270 |
Why?
| | Quality of Life | 2 | 2025 | 3211 | 0.250 |
Why?
| | Humans | 26 | 2026 | 145783 | 0.250 |
Why?
| | Administration, Intravesical | 1 | 2026 | 17 | 0.240 |
Why?
| | BCG Vaccine | 1 | 2026 | 27 | 0.240 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 467 | 0.230 |
Why?
| | Prostatic Hyperplasia | 1 | 2024 | 40 | 0.200 |
Why?
| | Male | 16 | 2025 | 73011 | 0.190 |
Why?
| | Middle Aged | 11 | 2025 | 36309 | 0.190 |
Why?
| | Lung Transplantation | 2 | 2017 | 332 | 0.190 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 76 | 0.180 |
Why?
| | Retrospective Studies | 8 | 2025 | 17330 | 0.180 |
Why?
| | Testicular Neoplasms | 1 | 2023 | 111 | 0.180 |
Why?
| | Treatment Outcome | 6 | 2025 | 11794 | 0.170 |
Why?
| | Office Visits | 1 | 2021 | 93 | 0.160 |
Why?
| | Female | 13 | 2025 | 79045 | 0.160 |
Why?
| | Venous Thrombosis | 1 | 2022 | 196 | 0.160 |
Why?
| | Lymph Node Excision | 1 | 2021 | 173 | 0.150 |
Why?
| | Guideline Adherence | 1 | 2024 | 587 | 0.150 |
Why?
| | Urinary Catheters | 1 | 2018 | 11 | 0.140 |
Why?
| | Constriction, Pathologic | 1 | 2020 | 249 | 0.140 |
Why?
| | Ciprofloxacin | 1 | 2018 | 31 | 0.140 |
Why?
| | Societies, Medical | 1 | 2023 | 900 | 0.140 |
Why?
| | Aged, 80 and over | 5 | 2025 | 8347 | 0.140 |
Why?
| | Venous Thromboembolism | 1 | 2022 | 328 | 0.130 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5925 | 0.130 |
Why?
| | Catheter-Related Infections | 1 | 2018 | 96 | 0.130 |
Why?
| | Antibiotic Prophylaxis | 1 | 2018 | 134 | 0.130 |
Why?
| | Neoplasm Staging | 2 | 2021 | 1475 | 0.120 |
Why?
| | Primary Graft Dysfunction | 1 | 2017 | 33 | 0.120 |
Why?
| | Self Report | 1 | 2021 | 876 | 0.120 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1582 | 0.120 |
Why?
| | Aspergillus | 1 | 2015 | 18 | 0.110 |
Why?
| | Postoperative Period | 1 | 2017 | 351 | 0.110 |
Why?
| | Aspergillosis | 1 | 2015 | 24 | 0.110 |
Why?
| | Voriconazole | 1 | 2015 | 21 | 0.110 |
Why?
| | Practice Patterns, Physicians' | 1 | 2024 | 1372 | 0.110 |
Why?
| | Disease-Free Survival | 1 | 2017 | 770 | 0.110 |
Why?
| | Prostatic Neoplasms | 2 | 2019 | 981 | 0.110 |
Why?
| | Postoperative Complications | 2 | 2025 | 2977 | 0.100 |
Why?
| | Preoperative Care | 1 | 2017 | 380 | 0.100 |
Why?
| | Patient Reported Outcome Measures | 1 | 2018 | 498 | 0.100 |
Why?
| | Graft Rejection | 1 | 2015 | 521 | 0.090 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2968 | 0.090 |
Why?
| | Research Design | 1 | 2018 | 1139 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2123 | 0.080 |
Why?
| | Proteins | 1 | 2017 | 1023 | 0.080 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2015 | 641 | 0.080 |
Why?
| | Time Factors | 1 | 2020 | 7134 | 0.070 |
Why?
| | United States | 2 | 2024 | 16126 | 0.070 |
Why?
| | Skin Neoplasms | 1 | 2015 | 853 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2018 | 1925 | 0.070 |
Why?
| | Cohort Studies | 1 | 2018 | 6033 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3916 | 0.060 |
Why?
| | Prospective Studies | 3 | 2025 | 8078 | 0.060 |
Why?
| | Quality Improvement | 2 | 2025 | 1296 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2025 | 311 | 0.050 |
Why?
| | Pelvis | 1 | 2025 | 125 | 0.050 |
Why?
| | Adult | 4 | 2025 | 40881 | 0.050 |
Why?
| | Enoxaparin | 1 | 2022 | 68 | 0.040 |
Why?
| | Aftercare | 1 | 2022 | 222 | 0.040 |
Why?
| | Pyridones | 1 | 2022 | 209 | 0.040 |
Why?
| | Databases, Factual | 1 | 2025 | 1491 | 0.040 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2018 | 29 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 733 | 0.040 |
Why?
| | Pyrazoles | 1 | 2022 | 517 | 0.030 |
Why?
| | Prostatectomy | 1 | 2018 | 94 | 0.030 |
Why?
| | Prostate-Specific Antigen | 1 | 2019 | 161 | 0.030 |
Why?
| | Geriatric Assessment | 1 | 2020 | 240 | 0.030 |
Why?
| | Prostate | 1 | 2018 | 159 | 0.030 |
Why?
| | Anticoagulants | 1 | 2022 | 748 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2019 | 627 | 0.030 |
Why?
| | Urinary Tract Infections | 1 | 2018 | 210 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 867 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1271 | 0.030 |
Why?
| | Patient Discharge | 1 | 2022 | 995 | 0.030 |
Why?
| | Radiosurgery | 1 | 2019 | 399 | 0.030 |
Why?
| | Antifungal Agents | 1 | 2015 | 152 | 0.030 |
Why?
| | Young Adult | 2 | 2025 | 14254 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2015 | 202 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2015 | 182 | 0.020 |
Why?
| | Graft Survival | 1 | 2015 | 519 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2934 | 0.020 |
Why?
| | Adolescent | 2 | 2025 | 22577 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 6085 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1764 | 0.020 |
Why?
| | Prognosis | 1 | 2015 | 4330 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2015 | 5428 | 0.010 |
Why?
| | Biomarkers | 1 | 2017 | 4302 | 0.010 |
Why?
| | Risk Factors | 1 | 2015 | 10919 | 0.010 |
Why?
| | Animals | 1 | 2017 | 38102 | 0.010 |
Why?
|
|
Kukreja's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|